COMP <GO>
ONTO vs TMO // NET PROFIT MARGIN
Onto Innovation Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: ONTO 4
— TMO 11
▲ NET PROFIT MARGIN LEADER: TMO
LAST: $201.57 (-9.16%) • MKT CAP: $10.89B
net-margins
0.00%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
net-margins
15.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ONTO VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ONTO | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 49.70% | 41.00% | +8.70 | ONTO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.60% | 9.30% | -3.70 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 67.8x | 30.4x | +37.40 | TMO | /valuation <GO> |
| Free Cash Flow Yield | 2.75% | 2.40% | +0.35 | ONTO | /fcf-yield <GO> |
| Operating Margin | 13.20% | 17.40% | -4.20 | TMO | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 0.00% | 15.10% | -15.10 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 1.80% | 3.90% | -2.10 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 4.50 | +21.50 | ONTO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.70% | +0.50 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.3 | 59.1 | -25.89 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.94 | +0.16 | ONTO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 36.3x | +103.70 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.89B | $262.22B | -$251.33B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ONTO REV | TMO REV | ONTO GROSS % | TMO GROSS % | ONTO FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.01B | $44.56B | 49.7% | 44.0% | $299.8M | $6.29B |
| FY 2024 | $987.3M | $42.88B | 52.2% | 44.0% | $213.8M | $7.27B |
| FY 2023 | $815.9M | $42.86B | 44.0% | 44.0% | $135.3M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ONTO // BETA 1.10
TMO // BETA 0.94